A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
ConclusionsFurther evaluations of gedatolisib are warranted in patients with advanced solid malignancies.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Endometrial Cancer | Ovarian Cancer | Ovaries | Study | Toxicology